CoChat

Rebound Insomnia: A Critical Review

GILLIN, J. CHRISTIAN, SPINWEBER, CHERYL L., JOHNSON, LAVERNE C. · 1989 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record, with a small difference in title or year.

Abstract

Rebound insomnia, a worsening of sleep compared with pretreatment levels, has been reported upon discontinuation of short half-life benzodiazepine hypnotics. This paper reviews the existing sleep laboratory studies for the presence or absence of rebound insomnia following treatment with triazolam, temazepam, and flurazepam in insomniac patients or poor sleepers and, when possible, in normals. The results indicate that rebound insomnia is a distinct possibility after discontinuation of triazolam in both insomniacs and normal controls. Compared with baseline, disturbed sleep was reported in insomniacs or poor sleepers for the first 1 or 2 nights of withdrawal in seven of nine polygraphically recorded sleep studies following triazolam 0.5 mg and in one of two studies following triazolam 0.25 mg. In one study conducted in normal volunteers, rebound insomnia was observed following triazolam 0.5 mg but not triazolam 0.25 mg. In another study, which used subjective reports of sleep rather than polygraphic recordings, rebound insomnia was significantly attenuated after triazolam 0.5 mg by tapering the dose over 4 nights. The risk of rebound insomnia after temazepam 15 or 30 mg was low. In keeping with its long elimination half-life, flurazepam (30 mg) continued to exert beneficial effects for the first 2-3 withdrawal nights, but the possibility of a mild rebound insomnia cannot be dismissed during the intermediate withdrawal period (nights 4-10) following prolonged, consecutive, nightly administration (more than 30 nights). The benzodiazepine hypnotics are generally preferred over other types (barbiturates or nonbenzodiazepine, nonbarbiturate), but there are advantages and disadvantages related to half-life of the benzodiazepines. The risk of rebound insomnia is greater with the short half-life as compared with the long half-life benzodiazepines.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-198906000-00002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 99

Metadata

Authors
GILLIN, J. C., SPINWEBER, C. L., & JOHNSON, L. C.
Affiliations
  • University of California San Diego (US)
  • Naval Health Research Center (US)
Venue
Journal of Clinical Psychopharmacology
Published
1989-06
Volume
9
Issue
3
Pages
161???172
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2043451114
Cited by
99
References
0
Citations by year
2026: 5 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 2 · 2012: 1
FWCI
6.25
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
rebound insomnia, benzodiazepine withdrawal, triazolam, temazepam, flurazepam, insomnia treatment, dose tapering, sleep disorders
MeSH terms
Flurazepam, Humans, Sleep Initiation and Maintenance Disorders, Sleep Stages, Substance Withdrawal Syndrome, Temazepam, Anti-Anxiety Agents, Triazolam

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rebound Insomnia: A Critical Review. https://app.cochat.ai/papers/10.1097/00004714-198906000-00002
The paper
GILLIN, J. C., SPINWEBER, C. L., & JOHNSON, L. C. (1989). Rebound Insomnia: A Critical Review. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198906000-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.